News

During the first week of February 2024, Arphio’s CEO, Dr. Shlomo Sadoun, was proud to be one of the key speakers participating at the prestigious Pharma Synergy event in London. With over 230 executives representing 62 countries in attendance, ...

In the realm of rare diseases, Dr. Shlomo Sadoun stands as an example of leadership, guiding Arphio towards excellence in orphan drug deployment. Recently recognized as one of "The 10 Most Innovative CEOs to Follow in 2024" by CIOViews magazine, Dr. ...

Following the recent recognition as one of "The 10 Most Innovative CEOs to Follow in 2024" by CIOViews magazine, Dr. Shlomo Sadoun, Arphio CEO, is charting a strategic course through the landscape of healthcare and orphan drugs. In this exploration, ...

In a strategic move to enhance our global footprint in orphan drug distribution, Arphio would like to share its ambitious outlook for 2024. Emphasising our commitment to making a significant impact on the global market for orphan ...

In a strategic move to enhance our global footprint in orphan drug distribution, Arphio would like to share its ambitious outlook for 2024.  Emphasising our commitment to making a significant impact on the global market for orphan drugs, Arphio...

In the landscape of the pharmaceutical industry, Research and Development (R&D) strategies play a pivotal role in driving innovation and addressing unmet medical needs. Arphio stands at the forefront of reshaping R&D to make a lasting impact ...

Arphio, in collaboration with Adalvo, is proud to introduce Ambrisentan + Tadalafil Film-Coated Tablets (5mg+20mg, 5mg+40mg, 10mg+40mg), an innovative treatment addressing the urgent unmet needs of patients with Pulmonary Arterial Hypertension. In a...

Arphio is thrilled to announce the appointment of David Olafsson as their interim Chief Financial Officer. David Olafsson brings a wealth of financial expertise and strategic leadership to Arphio. With an illustrious career in the finance sector, Da...

Adalvo, in collaboration with Arphio, is proud to introduce Teduglutide, a groundbreaking treatment addressing the urgent unmet needs of patients with Short Bowel Syndrome (SBS). Short Bowel Syndrome is a rare disease characterized by the inability ...

Arphio is pleased to announce that we have partnered with UK based niche generics company Colonis to bring Rybrila, a rare indication drug to patients in need within several emerging market territories.  Rybrila is an asset indicated in the sym...

The story behind Arphio is an interesting one. Two leading pharmaceutical companies partnering with the mission to improve access to vital treatments to patients suffering from rare diseases. When selecting the name and visual identity the mission a...

Aztiq and SK Pharma are thrilled to announce the recent establishment of a new entity ArphioTM, a powerhouse, solely dedicated to orphan drugs with the intention of improving access to vital treatments, to patients suffering from rare diseases and wi...